LifeVantage Corporation (LFVN) 10-Year Financial Performance & Capital Metrics

LFVN • • Industrial / General

Consumer DefensivePackaged FoodsNutritional Supplements & WellnessDietary Supplements & Vitamins

AboutLifeVantage Corporation engages in the identification, research, development, formulation, sale, and distribution of nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care products, bath and body, and targeted relief products. The company offers Protandim, a line of scientifically validated dietary supplements; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support digestive system health; a line of weight management products under the PhysIQ brand; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a line of energy drink mixes. It also provides anti-aging skin care products, including facial cleansers, perfecting lotions, eye serums, anti-aging creams, hand creams, beauty serum, as well as hair care products, such as invigorating shampoos, nourishing conditioners, and scalp serums under the LifeVantage TrueScience brand name. In addition, the company offers bath and body, and targeted relief products, such as body lotion, body wash, body butter, deodorant, soothing balm, and body rub under the TrueScience brand name. It sells its products through its website, as well as through a network of independent distributors in the United States, Mexico, Japan, Australia, Hong Kong, Canada, Thailand, the United Kingdom, the Netherlands, Germany, Taiwan, Austria, Spain, Ireland, Belgium, New Zealand, Singapore, and China. LifeVantage Corporation is headquartered in Lehi, Utah.Show more

Revenue $229M +14.2%
EBITDA $15M +94.0%
Net Income $10M +233.8%
EPS (Diluted) 0.76 +230.4%
Gross Margin 80.37% +1.4%
EBITDA Margin 6.72% +70.0%
Operating Margin 5.34% +146.7%
Net Margin 4.29% +192.4%
ROE 32.34% +233.9%
ROIC 37.47% +181.7%
Debt/Equity 0.34 -35.6%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Strong Piotroski F-Score: 7/9
✓High quality earnings: Operating CF exceeds net income
✓Good 3Y average ROE of 16.6%
✓Healthy dividend yield of 2.5%
✓Efficient asset utilization: 3.2x turnover

✗Weaknesses

✗Weak momentum: RS Rating 12 (bottom 12%)
✗Trading more than 30% below 52-week high

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y1.85%

5Y-0.38%

3Y3.46%

TTM22.32%

Profit (Net Income) CAGR

10Y3.45%

5Y-3.22%

3Y46.48%

TTM176.95%

EPS CAGR

10Y4.49%

5Y-0.77%

3Y46.85%

TTM170.44%

ROCE

10Y Avg32.29%

5Y Avg20.95%

3Y Avg16.35%

Latest29.49%

Peer Comparison

Dietary Supplements & Vitamins

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
SMPLThe Simply Good Foods Company	1.96B	21.15	20.74	8.98%	6.26%	5.23%	8.07%	0.17
FTLFFitLife Brands, Inc.	146.88M	15.64	17.23	22.33%	9.57%	16.13%	6.54%	0.37
USNAUSANA Health Sciences, Inc.	394.87M	21.60	9.86	-7.22%	1.86%	2.93%	12.9%	0.07
LFVNLifeVantage Corporation	80.4M	6.33	8.33	14.17%	4.78%	34.53%	13.07%	0.34
HLFHerbalife Nutrition Ltd.	1.72B	16.68	6.67	-1.37%	6.47%		9.48%
ATPCAgape ATP Corporation	5.45M	0.11	-0.17	-7.57%	-183%	-11.92%		0.19
HCWCHealthy Choice Wellness Corp.	5.38M	0.30	-0.62	24.57%	-5.44%	-73.95%		10.72

Profit & Loss

	Jun 2016	Jun 2017	Jun 2018	Jun 2019	Jun 2020	Jun 2021	Jun 2022	Jun 2023	Jun 2024	Jun 2025
Sales/Revenue+	206.54M	199.49M	203.2M	225.96M	232.91M	220.18M	206.36M	213.4M	200.16M	228.53M
Revenue Growth %	0.09%	-0.03%	0.02%	0.11%	0.03%	-0.05%	-0.06%	0.03%	-0.06%	0.14%
Cost of Goods Sold+	33.93M	33.46M	34.85M	37.97M	37.96M	38.19M	38.1M	43.39M	41.44M	44.86M
COGS % of Revenue	0.16%	0.17%	0.17%	0.17%	0.16%	0.17%	0.18%	0.2%	0.21%	0.2%
Gross Profit+	172.61M	166.03M	168.36M	187.99M	194.95M	181.99M	168.26M	170.01M	158.72M	183.67M
Gross Margin %	0.84%	0.83%	0.83%	0.83%	0.84%	0.83%	0.82%	0.8%	0.79%	0.8%
Gross Profit Growth %	0.06%	-0.04%	0.01%	0.12%	0.04%	-0.07%	-0.08%	0.01%	-0.07%	0.16%
Operating Expenses+	159.19M	161.58M	158.03M	178.17M	179.49M	164.38M	160.69M	165.75M	154.39M	171.47M
OpEx % of Revenue	0.77%	0.81%	0.78%	0.79%	0.77%	0.75%	0.78%	0.78%	0.77%	0.75%
Selling, General & Admin	159.19M	161.58M	158.03M	178.17M	179.49M	164.38M	63.42M	71.06M	68.47M	69.21M
SG&A % of Revenue	0.77%	0.81%	0.78%	0.79%	0.77%	0.75%	0.31%	0.33%	0.34%	0.3%
Research & Development	1M	1.1M	1.2M	1.1M	0	700K	0	0	0	0
R&D % of Revenue	0%	0.01%	0.01%	0%	-	0%	-	-	-	-
Other Operating Expenses	-1.41M	-969K	-319K	-261K	0	-700K	97.26M	94.69M	85.92M	102.26M
Operating Income+	13.41M	4.45M	10.32M	9.49M	15.47M	17.61M	7.58M	4.26M	4.33M	12.2M
Operating Margin %	0.06%	0.02%	0.05%	0.04%	0.07%	0.08%	0.04%	0.02%	0.02%	0.05%
Operating Income Growth %	-0.03%	-0.67%	1.32%	-0.08%	0.63%	0.14%	-0.57%	-0.44%	0.02%	1.82%
EBITDA+	15.31M	6.09M	11.65M	11.39M	20.57M	21.07M	10.84M	7.84M	7.91M	15.36M
EBITDA Margin %	0.07%	0.03%	0.06%	0.05%	0.09%	0.1%	0.05%	0.04%	0.04%	0.07%
EBITDA Growth %	-0.05%	-0.6%	0.91%	-0.02%	0.81%	0.02%	-0.49%	-0.28%	0.01%	0.94%
D&A (Non-Cash Add-back)	1.9M	1.64M	1.32M	1.9M	5.1M	3.46M	3.26M	3.58M	3.58M	3.16M
EBIT	12.01M	3.48M	10M	9.55M	14.78M	17.61M	4.7M	4.26M	4.33M	12.2M
Net Interest Income+	-3.32M	-570K	-456K	-323K	-120K	-17K	-10K	198K	430K	431K
Interest Income	0	0	0	0	0	0	0	198K	430K	431K
Interest Expense	3.32M	570K	456K	323K	120K	17K	10K	0	0	0
Other Income/Expense	-4.73M	-1.54M	-775K	-584K	-805K	-383K	-2.88M	-260K	18K	44K
Pretax Income+	8.68M	2.91M	9.55M	9.23M	14.66M	17.23M	4.69M	4M	4.35M	12.24M
Pretax Margin %	0.04%	0.01%	0.05%	0.04%	0.06%	0.08%	0.02%	0.02%	0.02%	0.05%
Income Tax+	2.67M	1.3M	3.79M	1.8M	3.11M	4.34M	1.57M	1.46M	1.41M	2.44M
Effective Tax Rate %	0.69%	0.55%	0.6%	0.8%	0.79%	0.75%	0.67%	0.64%	0.68%	0.8%
Net Income+	6.02M	1.61M	5.76M	7.43M	11.55M	12.89M	3.12M	2.54M	2.94M	9.8M
Net Margin %	0.03%	0.01%	0.03%	0.03%	0.05%	0.06%	0.02%	0.01%	0.01%	0.04%
Net Income Growth %	-0.14%	-0.73%	2.58%	0.29%	0.55%	0.12%	-0.76%	-0.19%	0.16%	2.34%
Net Income (Continuing)	6.11M	1.61M	5.76M	7.43M	11.55M	12.89M	3.12M	2.54M	2.94M	9.8M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	0.41	0.11	0.41	0.50	0.79	0.90	0.24	0.20	0.23	0.76
EPS Growth %	-0.16%	-0.73%	2.73%	0.22%	0.58%	0.14%	-0.73%	-0.17%	0.15%	2.3%
EPS (Basic)	0.44	0.12	0.41	0.53	0.82	0.92	0.24	0.20	0.24	0.80
Diluted Shares Outstanding	14.53M	14.12M	14.14M	14.98M	14.6M	14.27M	13.07M	12.57M	12.99M	12.99M
Basic Shares Outstanding	13.73M	13.88M	13.99M	14.05M	14.11M	14.07M	12.89M	12.56M	12.46M	12.25M
Dividend Payout Ratio	-	-	-	-	-	-	0.51%	0.62%	0.7%	0.21%

Balance Sheet

	Jun 2016	Jun 2017	Jun 2018	Jun 2019	Jun 2020	Jun 2021	Jun 2022	Jun 2023	Jun 2024	Jun 2025
Total Current Assets+	42.41M	35.55M	38.94M	43.19M	43.87M	48.05M	46.96M	44.28M	37.65M	50.89M
Cash & Short-Term Investments	7.88M	11.46M	16.65M	18.82M	22.14M	23.17M	20.19M	21.61M	16.89M	20.2M
Cash Only	7.88M	11.46M	16.65M	18.82M	22.14M	23.17M	20.19M	21.61M	16.89M	20.2M
Short-Term Investments	0	0	0	0	0	0	0	0	0	0
Accounts Receivable	1.55M	2.25M	2.52M	3.3M	2.61M	3.96M	5.09M	1.85M	3.26M	3.93M
Days Sales Outstanding	2.74	4.11	4.52	5.33	4.09	6.57	9	3.17	5.95	6.28
Inventory	25.12M	16.57M	13.63M	13.75M	13.89M	16.14M	16.47M	16.07M	15.05M	20.67M
Days Inventory Outstanding	270.17	180.83	142.73	132.2	133.52	154.32	157.82	135.22	132.6	168.16
Other Current Assets	2.26M	0	0	0	0	0	0	4.75M	2.44M	6.09M
Total Non-Current Assets+	7.85M	9.7M	12.2M	12.09M	15.01M	30.68M	23.75M	21.84M	22.65M	21.06M
Property, Plant & Equipment	3.46M	3.13M	6.59M	7.13M	8.13M	24.82M	20.54M	17.82M	17.38M	14.25M
Fixed Asset Turnover	59.76x	63.80x	30.85x	31.69x	28.66x	8.87x	10.05x	11.97x	11.52x	16.04x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	1.74M	1.25M	1.11M	983K	851K	719K	587K	455K	323K	245K
Long-Term Investments	0	0	0	0	2.21M	2.21M	0	0	0	0
Other Non-Current Assets	1.52M	1.24M	1.25M	1.28M	1.66M	1.72M	1.33M	569K	680K	601K
Total Assets+	50.26M	45.25M	51.14M	55.27M	58.88M	78.73M	70.71M	66.12M	60.3M	71.96M
Asset Turnover	4.11x	4.41x	3.97x	4.09x	3.96x	2.80x	2.92x	3.23x	3.32x	3.18x
Asset Growth %	0.23%	-0.1%	0.13%	0.08%	0.07%	0.34%	-0.1%	-0.06%	-0.09%	0.19%
Total Current Liabilities+	28.55M	23.36M	23.8M	26.2M	25.02M	25.2M	25.73M	19.61M	22.31M	27.22M
Accounts Payable	8.89M	4.85M	3.81M	5.18M	4.61M	7.59M	7.92M	4.22M	6.29M	5.06M
Days Payables Outstanding	95.64	52.91	39.94	49.79	44.33	72.56	75.91	35.54	55.38	41.16
Short-Term Debt	2M	2M	2M	1.45M	0	0	0	0	0	0
Deferred Revenue (Current)	1000K	1000K	1000K	998K	792K	319K	78K	834K	860K	711K
Other Current Liabilities	1.89M	12.2M	11.52M	1.06M	4.55M	1.5M	971K	3.1M	1.61M	5.33M
Current Ratio	1.49x	1.52x	1.64x	1.65x	1.75x	1.91x	1.83x	2.26x	1.69x	1.87x
Quick Ratio	0.61x	0.81x	1.06x	1.12x	1.20x	1.27x	1.18x	1.44x	1.01x	1.11x
Cash Conversion Cycle	177.27	132.03	107.32	87.74	93.28	88.33	90.91	102.84	83.18	133.27
Total Non-Current Liabilities+	9.58M	7.37M	5.39M	1.88M	604K	16.73M	13.46M	11.87M	12M	10.1M
Long-Term Debt	7.41M	5.44M	3.41M	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	0	16.03M	13.15M	11.57M	11.8M	9.81M
Deferred Tax Liabilities	1.13M	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	2.17M	1.93M	1.98M	1.88M	604K	694K	308K	299K	198K	289K
Total Liabilities	38.13M	30.72M	29.2M	28.07M	25.62M	41.92M	39.19M	31.47M	34.31M	37.32M
Total Debt+	9.41M	7.44M	5.41M	1.45M	1.18M	18.18M	15.76M	13.09M	13.61M	11.68M
Net Debt	1.53M	-4.02M	-11.24M	-17.37M	-20.95M	-4.99M	-4.43M	-8.52M	-3.27M	-8.52M
Debt / Equity	0.78x	0.51x	0.25x	0.05x	0.04x	0.49x	0.50x	0.38x	0.52x	0.34x
Debt / EBITDA	0.61x	1.22x	0.46x	0.13x	0.06x	0.86x	1.45x	1.67x	1.72x	0.76x
Net Debt / EBITDA	0.10x	-0.66x	-0.96x	-1.53x	-1.02x	-0.24x	-0.41x	-1.09x	-0.41x	-0.56x
Interest Coverage	4.04x	7.81x	22.64x	29.38x	128.88x	1036.18x	757.50x	-	-	-
Total Equity+	12.13M	14.53M	21.95M	27.2M	33.25M	36.81M	31.52M	34.65M	25.99M	34.64M
Equity Growth %	2.65%	0.2%	0.51%	0.24%	0.22%	0.11%	-0.14%	0.1%	-0.25%	0.33%
Book Value per Share	0.83	1.03	1.55	1.82	2.28	2.58	2.41	2.76	2.00	2.67
Total Shareholders' Equity	12.13M	14.53M	21.95M	27.2M	33.25M	36.81M	31.52M	34.65M	25.99M	34.64M
Common Stock	14K	14K	1K	1K	1K	1K	1K	1K	1K	1K
Retained Earnings	-108.08M	-106.99M	-102.73M	-99.96M	-93.31M	-92.35M	-98.44M	-98.31M	-108.74M	-104.15M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	43K	-94K	14K	62K	144K	104K	-1.12M	-1.36M	-1.92M	-1.18M
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Jun 2016	Jun 2017	Jun 2018	Jun 2019	Jun 2020	Jun 2021	Jun 2022	Jun 2023	Jun 2024	Jun 2025
Cash from Operations+	5.99M	6.6M	13.26M	17.79M	18.33M	16.27M	6.83M	6.83M	11.88M	11.88M
Operating CF Margin %	0.03%	0.03%	0.07%	0.08%	0.08%	0.07%	0.03%	0.03%	0.06%	0.05%
Operating CF Growth %	-0.55%	0.1%	1.01%	0.34%	0.03%	-0.11%	-0.58%	0%	0.74%	0%
Net Income	6.02M	1.61M	5.76M	7.43M	11.55M	12.89M	2.54M	2.54M	9.8M	9.8M
Depreciation & Amortization	1.9M	1.64M	1.32M	1.9M	5.15M	5.83M	3.58M	5.33M	3.16M	3.16M
Stock-Based Compensation	2.62M	2.65M	3.2M	5.53M	4.92M	2.04M	3.19M	3.19M	5.7M	5.7M
Deferred Taxes	-2.55M	-740K	831K	563K	0	0	-1.7M	0	-1.7M	-1.7M
Other Non-Cash Items	3.15M	381K	32K	42K	146K	3.17M	1.78M	-4.59M	1.47M	1.47M
Working Capital Changes	-5.14M	1.06M	2.11M	2.33M	-3.43M	-7.65M	-2.56M	367K	-6.55M	-6.55M
Change in Receivables	1.77M	160K	-730K	14K	-539K	-265K	3.07M	1.56M	-564K	-564K
Change in Inventory	-15.65M	8.31M	2.95M	-64K	-152K	-2.07M	61K	61K	-5.22M	-5.22M
Change in Payables	3.67M	-6.21M	-1.02M	1.37M	0	0	-3.98M	0	-1.29M	-1.29M
Cash from Investing+	-562K	-1.05M	-4.65M	-4.51M	-2.68M	-3.73M	-3.06M	-3.06M	-1.37M	-1.37M
Capital Expenditures	-562K	-1.05M	-4.65M	-2.51M	-2.68M	-3.74M	-3.07M	-3.07M	-1.37M	-1.37M
CapEx % of Revenue	0%	0.01%	0.02%	0.01%	0.01%	0.02%	0.01%	0.01%	0.01%	0.01%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-562K	-1.05M	-4.65M	-2M	0	7K	8K	8K	4K	0
Cash from Financing+	-11.7M	-1.96M	-3.5M	-11.12M	-12.42M	-11.45M	-2.36M	-2.36M	-7.6M	-7.6M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	-1.59M	-1.59M	-2.07M	-2.07M
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	428K	42K	1K	701K	729K	1.9M	252K	252K	280K	-2.66M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	5.42M	5.54M	8.61M	15.28M	15.64M	12.53M	3.76M	3.76M	10.51M	10.51M
FCF Margin %	0.03%	0.03%	0.04%	0.07%	0.07%	0.06%	0.02%	0.02%	0.05%	0.05%
FCF Growth %	-0.55%	0.02%	0.55%	0.78%	0.02%	-0.2%	-0.7%	0%	1.79%	0%
FCF per Share	0.37	0.39	0.61	1.02	1.07	0.88	0.29	0.30	0.81	0.81
FCF Conversion (FCF/Net Income)	0.99x	4.10x	2.30x	2.39x	1.59x	1.26x	2.19x	2.69x	4.04x	1.21x
Interest Paid	1.34M	438K	345K	227K	44K	17K	5K	5K	2K	2K
Taxes Paid	1.37M	5.5M	2.87M	1.29M	0	0	1.87M	0	4.92M	4.92M

Key Ratios

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Return on Equity (ROE)	77.89%	12.06%	31.59%	30.23%	38.21%	36.81%	9.13%	7.68%	9.69%	32.34%
Return on Invested Capital (ROIC)	84.37%	27.62%	72.98%	69.32%	104.84%	59.89%	19.29%	12.01%	13.3%	37.47%
Gross Margin	83.57%	83.23%	82.85%	83.19%	83.7%	82.66%	81.54%	79.67%	79.3%	80.37%
Net Margin	2.91%	0.81%	2.84%	3.29%	4.96%	5.86%	1.51%	1.19%	1.47%	4.29%
Debt / Equity	0.78x	0.51x	0.25x	0.05x	0.04x	0.49x	0.50x	0.38x	0.52x	0.34x
Interest Coverage	4.04x	7.81x	22.64x	29.38x	128.88x	1036.18x	757.50x	-	-	-
FCF Conversion	0.99x	4.10x	2.30x	2.39x	1.59x	1.26x	2.19x	2.69x	4.04x	1.21x
Revenue Growth	8.51%	-3.41%	1.86%	11.2%	3.08%	-5.47%	-6.28%	3.41%	-6.2%	14.17%

Revenue by Segment

	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Protandim	128.02M	130.87M	133.92M	155.5M	156.34M	150.27M	135.62M	119.72M	104.14M	95.33M
Protandim Growth	-	2.23%	2.33%	16.11%	0.54%	-3.88%	-9.75%	-11.72%	-13.02%	-8.46%
LifeVantage TrueScience Skin Care Regimen	32.91M	24.44M	21.66M	20.88M	23.74M	22.62M	22.88M	49.49M	56.25M	56.23M
LifeVantage TrueScience Skin Care Regimen Growth	-	-25.75%	-11.35%	-3.62%	13.69%	-4.73%	1.15%	116.35%	13.65%	-0.05%
Product and Service, Other	-	-	-	49.58M	52.84M	47.29M	47.87M	44.18M	39.78M	5.73M
Product and Service, Other Growth	-	-	-	-	6.58%	-10.50%	1.22%	-7.69%	-9.97%	-85.58%
Other Product Lines	45.61M	44.18M	47.62M	-	-	-	-	-	-	-
Other Product Lines Growth	-	-3.14%	7.79%	-	-	-	-	-	-	-

Revenue by Geography

	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
UNITED STATES	152.83M	144.84M	142.45M	151.97M	155.48M	144.9M	130.93M	148.52M	145.68M	178.44M
UNITED STATES Growth	-	-5.23%	-1.65%	6.68%	2.31%	-6.81%	-9.64%	13.43%	-1.91%	22.49%
Non-US	-	-	-	-	-	-	-	-	-	50.09M
Non-US Growth	-	-	-	-	-	-	-	-	-	-
JAPAN	36.34M	39.39M	41.84M	40.8M	42.34M	41.17M	36.81M	32.08M	26.99M	25.39M
JAPAN Growth	-	8.38%	6.23%	-2.50%	3.79%	-2.76%	-10.60%	-12.84%	-15.87%	-5.91%
Other Foreign	-	-	-	-	-	-	-	-	-	24.69M
Other Foreign Growth	-	-	-	-	-	-	-	-	-	-
Americas	158.29M	150.84M	151.61M	163.24M	166.34M	154.66M	138.32M	155.36M	152.91M	-
Americas Growth	-	-4.71%	0.51%	7.67%	1.90%	-7.02%	-10.56%	12.32%	-1.58%	-
Asia Pacific And Europe	-	-	-	62.72M	66.58M	65.53M	68.04M	58.04M	47.26M	-
Asia Pacific And Europe Growth	-	-	-	-	6.15%	-1.58%	3.83%	-14.70%	-18.57%	-
Asia/Pacific And Europe	-	48.65M	51.59M	-	-	-	-	-	-	-
Asia/Pacific And Europe Growth	-	-	6.06%	-	-	-	-	-	-	-
Asia and Pacific	48.25M	-	-	-	-	-	-	-	-	-
Asia and Pacific Growth	-	-	-	-	-	-	-	-	-	-

Frequently Asked Questions

Valuation & Price

LifeVantage Corporation (LFVN) has a price-to-earnings (P/E) ratio of 8.3x. This may indicate the stock is undervalued or faces growth challenges.

Growth & Financials

LifeVantage Corporation (LFVN) reported $239.8M in revenue for fiscal year 2025. This represents a 90% increase from $126.2M in 2012.

LifeVantage Corporation (LFVN) grew revenue by 14.2% over the past year. This is steady growth.

Yes, LifeVantage Corporation (LFVN) is profitable, generating $11.4M in net income for fiscal year 2025 (4.3% net margin).

Dividend & Returns

Yes, LifeVantage Corporation (LFVN) pays a dividend with a yield of 2.51%. This makes it attractive for income-focused investors.

LifeVantage Corporation (LFVN) has a return on equity (ROE) of 32.3%. This is excellent, indicating efficient use of shareholder capital.

LifeVantage Corporation (LFVN) generated $8.7M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

US Stock Screener

...